7Baggers

Corvus Pharmaceuticals, Inc
(NASDAQ:CRVS) 

CRVS stock logo

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of aden...

Founded: 2014
Full Time Employees: 52
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-09-30 2016-06-30 2016-03-31 
                                           
      operating expenses:
    		                                       
      research and development
    		11,175,000 9,939,000 8,454,000 7,873,000 7,453,000 5,974,000 5,222,000 4,114,000 4,075,000 3,999,000 3,965,000 3,968,000 4,594,000 4,080,000 10,365,000 4,923,000 5,100,000 4,788,000 6,991,000 9,106,000 8,230,000 7,191,000 6,619,000 7,857,000 10,163,000 8,920,000 8,996,000 10,640,000 9,419,000 8,394,000 8,374,000 9,715,000 12,103,000 10,733,000 12,386,000 13,497,000 7,707,000 7,119,000 5,397,000 
      general and administrative
    		3,702,000 2,278,000 2,118,000 2,387,000 2,469,000 2,131,000 2,033,000 1,821,000 2,178,000 1,652,000 1,595,000 1,654,000 1,980,000 1,586,000 2,108,000 2,090,000 2,313,000 2,022,000 2,056,000 2,184,000 3,253,000 2,688,000 3,226,000 2,910,000 3,106,000 2,520,000 2,517,000 2,956,000 2,886,000 2,777,000 2,775,000 2,543,000 2,541,000 2,211,000 2,788,000 2,720,000 2,769,000 1,706,000 1,029,000 
      total operating expenses
    		14,877,000 12,217,000 10,572,000 10,260,000 9,922,000 8,105,000 7,255,000 5,935,000 6,253,000 5,651,000 5,560,000 5,622,000 6,574,000 5,666,000 12,473,000 7,013,000 7,413,000 6,810,000 9,047,000 11,290,000 11,483,000 9,879,000 9,845,000 10,767,000 13,269,000 11,440,000 11,513,000 13,596,000 12,305,000 11,171,000 11,149,000 12,258,000 14,644,000 12,944,000 15,174,000 16,217,000 10,476,000 8,825,000 6,426,000 
      income from operations
    		-14,877,000 -12,217,000 -10,572,000 -10,260,000 -9,922,000 -8,105,000 -7,255,000 -5,935,000 -6,253,000 -5,651,000 -5,560,000 -5,622,000 -6,574,000 -5,666,000 -12,473,000 -7,013,000 -7,413,000 -6,810,000 -9,047,000 -11,290,000 -11,483,000 -9,879,000 -9,845,000 -10,767,000 -13,269,000 -11,440,000 -11,513,000 -13,596,000 -12,305,000 -11,171,000 -11,149,000 -12,258,000        
      yoy
    		49.94% 50.73% 45.72% 72.87% 58.68% 43.43% 30.49% 5.57% -4.88% -0.26% -55.42% -19.83% -11.32% -16.80% 37.87% -37.88% -35.44% -31.07% -8.11% 4.86% -13.46% -13.65% -14.49% -20.81% 7.83% 2.41% 3.26% 10.92%            
      qoq
    		21.77% 15.56% 3.04% 3.41% 22.42% 11.72% 22.24% -5.09% 10.65% 1.64% -1.10% -14.48% 16.03% -54.57% 77.86% -5.40% 8.85% -24.73% -19.87% -1.68% 16.24% 0.35% -8.56% -18.86% 15.99% -0.63% -15.32% 10.49% 10.15% 0.20% -9.05%         
      interest income and other expense
    		1,784,000 603,000 738,000 639,000 525,000 508,000 566,000 434,000 316,000 380,000 425,000 403,000 376,000 318,000 225,000 100,000 11,000 -8,000 -11,000 1,000 3,000 1,000 49,000 156,000 334,000 393,000 509,000 618,000 662,000 662,000 651,000 627,000     179,000   
      change in fair value of warrant liability
    		   2,012,000 25,129,000 -2,347,000 -32,846,000 1,816,000                                
      loss before equity method investment
    		-13,093,000 -11,614,000 -9,834,000   -9,939,000 -39,535,000 -3,685,000 -5,937,000                               
      loss from equity method investment
    		-599,000 -707,000 -323,000 -389,000  -2,174,000 -682,000 -577,000  -1,404,000 -865,000 -1,284,000 -1,731,000 -4,638,000 -2,730,000 -1,596,000 -1,041,000 -2,559,000 -1,709,000 -463,000 -100,000                   
      net income
    		-13,692,000 -12,321,000 -10,157,000 -7,998,000 15,193,000 -12,113,000 -40,217,000 -4,262,000 -5,701,000 -6,653,000 -6,000,000 -6,503,000 -7,873,000 -9,816,000 -14,831,000 -8,363,000 -8,297,000 -9,236,000 -10,673,000 -11,752,000 -11,580,000 27,347,000 -9,796,000 -10,611,000 -12,935,000 -11,047,000 -11,004,000 -12,978,000 -11,643,000 -10,509,000 -10,498,000 -11,631,000 -14,301,000 -12,717,000 -14,981,000 -16,036,000 -10,297,000 -8,645,000 -6,347,000 
      yoy
    		-190.12% 1.72% -74.74% 87.66% -366.50% 82.07% 570.28% -34.46% -27.59% -32.22% -59.54% -22.24% -5.11% 6.28% 38.96% -28.84% -28.35% -133.77% 8.95% 10.75% -10.48% -347.55% -10.98% -18.24% 11.10% 5.12% 4.82% 11.58% -18.59% -17.36% -29.92% -27.47% 38.89% 47.10% 136.03%     
      qoq
    		11.13% 21.31% 26.99% -152.64% -225.43% -69.88% 843.62% -25.24% -14.31% 10.88% -7.73% -17.40% -19.79% -33.81% 77.34% 0.80% -10.17% -13.46% -9.18% 1.49% -142.34% -379.16% -7.68% -17.97% 17.09% 0.39% -15.21% 11.47% 10.79% 0.10% -9.74% -18.67% 12.46% -15.11% -6.58% 55.73% 19.11% 36.21%  
      net income per share
    		-0.15 -0.15 -0.12 -0.1 0.21 -0.16 -0.6 -0.07 -0.12 -0.13 -0.12 -0.14 -0.17 -0.21 -0.32 -0.18 -0.18 -0.19 -0.24 -0.28 -0.34 0.93 -0.33 -0.36 -0.44 -0.38 -0.37 -0.44 -0.4 -0.36 -0.36 -0.4 -0.63 -0.62 -0.73 -0.79 -0.51 -0.43 -5.39 
      shares used to compute net income per share, basic
    		89,996,728   77,774,344 72,126,496                                   
      shares used to compute net loss per share, diluted
    		89,996,728 1,087,261 82,836,369 77,774,344 75,152,514                                   
      other comprehensive income:
    		                                       
      unrealized loss on marketable securities
    		-334    -23           -54                        
      cumulative foreign currency translation adjustment
    		104 168 59 125 57 -473 465 -85 -293 455 -80 -933 88 601 -1,537 -1,594 146 497 -10 1,385                    
      comprehensive income
    		-13,922   -7,892 15,227                                   
      shares used to compute net loss per share, basic
    		 1,346,542 82,836,369                                     
      other comprehensive loss:
    		                                       
      unrealized gain on marketable securities
    		 -4 29 -19  -77 152 5 -15 21 5 -1 41 -19.25 5  -28 -3 -2 -4 2 -8 -41 10 14 -5  28 45 1 -15 19  38 11   49 74 
      comprehensive loss
    		 -12,157 -10,069   -12,663 -39,600 -4,342 -6,009 -6,177 -6,075 -7,437 -7,744 -9,186 -16,363 -10,011 -8,179 -8,742 -10,685 -10,371 -11,578 27,339 -9,837 -10,601 -12,921 -11,052 -11,009 -12,950 -11,598 -10,508 -10,513 -11,612 -14,303 -12,679 -14,970 -16,059 -10,333 -8,596 -6,273 
      income before equity method investment
    		   -7,609,000 15,732,000                                   
      income from equity method investment
    		    -539,000    236,000                               
      sublease income - related party
    		         22,000   56,000 148,000 147,000 146,000 146,000 141,000 94,000                     
      shares used to compute net loss per share, basic and diluted
    		     2,471,862 66,701,086 59,710,265 49,038,582 341,482 48,971,246 47,497,414 46,556,178  46,553,511 46,553,511 46,553,511 1,583,156 43,947,004 42,247,094 34,515,116 59,447 29,500,318 29,428,249 29,411,233 18,520 29,389,003 29,309,150 29,292,135 603,497 29,087,129 28,979,514 22,580,620 20,501,382 20,426,849 20,349,391 20,183,497 19,959,459 1,176,546 
      interest income
    		                                343,000 227,000 193,000 181,000  180,000 79,000 
      other comprehensive income
    		                                       
      change in fair value of convertible preferred stock liability
    		                                       
      total other comprehensive income
    		                                     49 74 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-09-30 2016-06-30 2016-03-31 
                                             
        assets
      		                                       
        current assets:
      		                                       
        cash and cash equivalents
      		40,102,000 4,576,000 2,867,000 14,691,000 4,999,000 8,740,000 4,680,000 14,841,000 7,456,000 12,620,000 20,105,000 7,658,000 9,654,000 13,159,000 24,588,000 28,477,000 31,460,000 63,458,000 72,295,000 58,915,000 45,104,000 16,455,000 22,976,000 20,705,000 23,498,000 5,154,000 9,067,000 30,183,000 38,976,000 39,196,000 40,747,000 28,068,000 102,565,000 44,104,000 34,095,000 10,487,000 5,576,000 4,343,000 4,065,000 
        marketable securities
      		196,612,000 52,174,000 62,822,000 59,716,000 39,213,000 43,224,000 36,971,000 32,405,000 14,672,000 14,529,000 12,063,000 29,359,000 24,813,000 29,144,000 25,029,000 28,246,000 31,484,000 5,993,000 4,034,000 7,545,000 22,865,000 27,804,000 28,385,000 38,553,000 45,209,000 72,828,000 77,354,000 66,657,000 66,831,000 75,401,000 81,892,000 105,157,000 41,368,000 55,596,000 76,231,000 111,577,000 139,547,000 147,809,000 148,235,000 
        accounts receivable - related party
      		43,000 37,000 32,000 86,000 79,000 75,000 70,000 35,000 26,000 26,000 11,000  429,000 588,000 503,000 373,000 373,000 507,000 276,000                     
        prepaid and other current assets
      		3,189,000 1,427,000 1,223,000 1,287,000 1,200,000 2,368,000 1,200,000 977,000 697,000 781,000 915,000 893,000 655,000 773,000 1,152,000 1,789,000 1,050,000 1,354,000 2,152,000 2,660,000 840,000 1,077,000 1,148,000 1,303,000 1,136,000 1,362,000 1,411,000 1,305,000 1,197,000 992,000 1,893,000 1,208,000 1,233,000 1,167,000 1,308,000 1,051,000 913,000 1,343,000 1,772,000 
        total current assets
      		239,946,000 58,214,000 66,944,000 75,780,000 45,491,000 54,407,000 42,921,000 48,258,000 22,851,000 27,956,000 33,094,000 37,910,000 35,551,000 43,664,000 51,272,000 58,885,000 64,367,000 71,312,000 78,757,000 69,120,000 68,809,000 45,336,000 52,509,000 60,561,000 69,843,000 79,344,000 87,832,000 98,145,000 107,004,000 115,589,000 124,532,000 134,433,000 145,166,000 100,867,000 111,634,000 123,115,000 146,036,000 153,495,000 154,072,000 
        property and equipment
      		282,000 220,000 221,000 249,000 165,000 151,000 171,000 192,000 213,000 236,000 264,000 294,000 330,000 353,000 447,000 527,000 364,000 451,000 539,000 647,000 769,000 906,000 1,048,000 1,119,000 1,278,000 1,462,000 1,642,000 1,824,000 2,010,000 2,180,000 2,226,000 2,293,000 2,459,000 2,863,000 2,984,000 3,117,000 2,858,000 2,807,000 2,552,000 
        operating lease right-of-use asset
      		751,000 839,000 927,000 1,012,000 1,095,000 1,177,000 284,000 578,000 865,000 1,149,000 1,423,000 1,691,000 1,953,000 2,217,000 2,467,000 2,712,000 2,952,000 3,190,000 3,420,000 1,264,000 1,455,000 1,648,000 1,825,000 1,996,000 2,163,000 2,327,000 2,483,000 2,634,000 2,781,000           
        investment in angel pharmaceuticals
      		10,496,000 10,991,000 11,530,000 11,794,000 12,058,000 12,540,000 15,187,000 15,404,000 16,066,000 16,123,000 17,072,000 18,017,000 20,234,000 21,877,000 25,914,000 30,181,000 33,371,000 34,266,000 36,328,000 38,047,000 37,125,000 37,225,000                  
        other assets
      		1,720,000 855,000 852,000 626,000 629,000 632,000 252,000 129,000 89,000 89,000 89,000 129,000 129,000 129,000 248,000 236,000 236,000 236,000 279,000 316,000 1,078,000 414,000 480,000 501,000 513,000 513,000 513,000 513,000 514,000 463,000 464,000 1,193,000 1,064,000 1,058,000 869,000 869,000 869,000 619,000 600,000 
        total assets
      		253,195,000 71,119,000 80,474,000 89,461,000 59,438,000 68,907,000 58,815,000 64,561,000 40,084,000 45,553,000 51,942,000 58,041,000 58,197,000 68,240,000 80,348,000 92,541,000 101,290,000 109,455,000 119,323,000 109,394,000 109,236,000 85,529,000 55,862,000 64,177,000 73,797,000 83,646,000 92,470,000 103,116,000 112,309,000 118,232,000 127,222,000 137,919,000 148,689,000 104,788,000 115,487,000 127,101,000 149,763,000 156,921,000 157,224,000 
        liabilities and stockholders’ equity
      		                                       
        current liabilities:
      		                                       
        accounts payable
      		4,697,000 2,491,000 1,974,000 3,137,000 1,308,000 2,582,000 1,873,000 1,213,000 1,609,000 1,525,000 1,404,000 2,098,000 1,407,000 1,976,000 4,227,000 2,650,000 2,189,000 1,565,000 2,334,000 2,865,000 4,910,000 3,467,000 2,571,000 2,779,000 3,356,000 2,448,000 1,910,000 2,638,000 2,264,000 1,998,000 1,885,000 2,255,000 3,499,000 3,576,000 4,138,000 2,421,000 2,416,000 1,320,000 1,577,000 
        operating lease liability
      		428,000 403,000 379,000 355,000 319,000 185,000 354,000 700,000 1,040,000 1,374,000 1,336,000 1,299,000 1,263,000 1,228,000 1,181,000 1,135,000 1,090,000 1,046,000 1,015,000 1,153,000 1,115,000 1,078,000 1,026,000 976,000 927,000 878,000 849,000 820,000 792,000           
        accrued and other liabilities
      		6,985,000 6,486,000 5,721,000 5,013,000 3,871,000 3,725,000 4,215,000 4,304,000 4,071,000 3,970,000 4,559,000 4,461,000 5,620,000 7,548,000 8,570,000 6,371,000 5,986,000 7,081,000 7,956,000 8,342,000 7,891,000 7,604,000 8,404,000 7,798,000 7,429,000 6,899,000 6,760,000 7,244,000 5,579,000 5,029,000 5,863,000 7,524,000 7,105,000 6,398,000 5,380,000 5,158,000 3,180,000 2,287,000 1,806,000 
        total current liabilities
      		12,110,000 9,380,000 8,074,000 8,505,000 9,279,000 35,402,000 46,406,000 13,335,000 6,720,000 6,869,000 7,299,000 7,858,000 8,290,000 10,752,000 13,978,000 10,156,000 9,265,000 9,692,000 11,305,000 12,360,000 13,916,000 12,149,000 12,001,000 11,553,000 11,712,000 10,225,000 9,519,000 10,702,000 8,635,000 7,027,000 7,748,000 9,779,000 10,604,000 9,974,000 9,518,000 7,579,000 5,596,000 3,607,000 3,383,000 
        total liabilities
      		12,516,000 9,914,000 8,706,000 9,233,000 10,113,000 36,339,000 46,406,000 13,335,000 6,720,000 6,869,000 7,653,000 8,558,000 9,330,000 12,125,000 15,667,000 12,155,000 11,568,000 12,293,000 14,175,000 12,991,000 14,851,000 13,381,000 13,512,000 13,337,000 13,762,000 12,535,000 12,057,000 13,462,000 11,612,000 7,896,000 8,375,000 10,520,000 11,461,000 11,051,000 10,705,000 8,876,000 6,853,000 4,953,000 4,674,000 
        commitments and contingencies
      		                                       
        stockholders’ equity:
      		                                       
        preferred stock: 0.0001 par value...
      		                                       
        common stock: 0.0001 par value...
      		8,000 7,000 7,000 7,000 7,000 7,000 6,000 6,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 5,000 4,000 4,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 2,000 2,000 2,000 2,000 2,000 2,000 
        additional paid-in capital
      		667,782,000 474,387,000 472,793,000 471,184,000 432,389,000 430,859,000 398,038,000 397,255,000 375,052,000 374,363,000 373,791,000 372,910,000 364,857,000 364,361,000 363,741,000 363,083,000 362,408,000 361,669,000 360,913,000 341,484,000 329,095,000 295,281,000 292,822,000 291,475,000 290,069,000 288,224,000 286,474,000 284,706,000 282,799,000 280,840,000 278,842,000 276,882,000 275,099,000 205,354,000 203,720,000 202,192,000 199,652,000 198,376,000 190,362,000 
        accumulated other comprehensive loss
      		-1,126,000 -896,000 -1,060,000 -1,148,000 -1,254,000 -1,288,000 -738,000 -1,355,000 -1,275,000 -967,000 -1,443,000 -1,368,000 -434,000                 -34,000 -35,000 -20,000        
        accumulated deficit
      		-425,985,000 -412,293,000 -399,972,000 -389,815,000 -381,817,000 -397,010,000 -384,897,000 -344,680,000 -340,418,000 -334,717,000 -328,064,000 -322,064,000 -315,561,000 -307,688,000 -297,872,000 -283,041,000 -274,678,000 -266,381,000 -257,145,000 -246,472,000 -234,720,000 -223,140,000 -250,487,000 -240,691,000 -230,080,000 -217,145,000 -206,098,000 -195,094,000 -182,116,000 -170,473,000 -159,963,000 -149,466,000        
        total stockholders’ equity
      		240,679,000 61,205,000 71,768,000 80,228,000 49,325,000 32,568,000 12,409,000 51,226,000 33,364,000 38,684,000 44,289,000 49,483,000 48,867,000 56,115,000 64,681,000 80,386,000 89,722,000 97,162,000 105,148,000 96,403,000 94,385,000 72,148,000 42,350,000 50,840,000 60,035,000 71,111,000 80,413,000 89,654,000 100,697,000 110,336,000 118,847,000 127,399,000 137,228,000 93,737,000 104,782,000 118,225,000 142,910,000 151,968,000 152,550,000 
        total liabilities and stockholders’ equity
      		253,195,000 71,119,000 80,474,000 89,461,000 59,438,000 68,907,000 58,815,000 64,561,000 40,084,000 45,553,000 51,942,000 58,041,000 58,197,000 68,240,000 80,348,000 92,541,000 101,290,000 109,455,000 119,323,000 109,394,000 109,236,000 85,529,000 55,862,000 64,177,000 73,797,000 83,646,000 92,470,000 103,116,000 112,309,000 118,232,000 127,222,000 137,919,000 148,689,000 104,788,000 115,487,000 127,101,000    
        warrant liability
      		    3,781,000 28,910,000 39,964,000 7,118,000                                
        accumulated other comprehensive income
      		             -563,000 -1,193,000 339,000 1,987,000 1,869,000 1,375,000 1,387,000 6,000 4,000 12,000 53,000 43,000 29,000 34,000 39,000 11,000        41,000 78,000 29,000 
        other liabilities
      		                             869,000 627,000 741,000 857,000 1,077,000 1,187,000 1,297,000 1,257,000 1,346,000 1,291,000 
        deferred offering costs
      		                                       
        liabilities, convertible preferred stock, and stockholders’ equity
      		                                       
        convertible preferred stock: 0.0001 par value...
      		                                       
        stockholders’ equity (deficit) :
      		                                       
        total liabilities, convertible preferred stock and stockholders’ equity
      		                                    149,763,000 156,921,000 157,224,000 
                                             
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-09-30 2016-06-30 2016-03-31 
                                               
          cash flows from operating activities
        		                                       
          net loss
        		-13,692,000 -12,321,000    -12,113,000 -40,217,000 -4,262,000 -5,701,000 -6,653,000 -6,000,000 -6,503,000 -7,873,000 -9,816,000 -14,831,000 -8,363,000 -8,297,000 -9,236,000 -10,673,000 -11,752,000 -11,580,000 27,347,000 -9,796,000 -10,611,000 -12,935,000 -11,047,000 -11,004,000 -12,978,000 -11,643,000 -10,509,000 -10,498,000 -11,631,000 -14,301,000 -12,717,000 -14,981,000 -16,036,000 -10,297,000 -8,645,000 -6,347,000 
          adjustments to reconcile net loss to net cash from operating activities:
        		                                       
          depreciation and amortization
        		29,000 26,000 28,000 29,000 22,000 20,000 21,000 21,000 23,000 28,000 30,000 36,000 57,000 94,000 94,000 92,000 87,000 93,000 108,000 122,000 137,000 142,000 147,000 159,000 184,000 185,000 186,000 186,000 186,000 180,000 228,000 220,000 219,000       
          accretion related to marketable securities
        		-17,000 -261,000 -459,000 -334,000 -291,000 -242,000 -524,000 -224,000 -151,000 -127,000 -245,000 -258,000 -264,000 -182,000 -83,000 40,000 55,000 32,000 38,000 74,000 95,000 110,000 112,000 -4,000 -64,000 -79,000 -181,000 -214,000 -170,000 -171,000 -205,000         
          stock-based compensation
        		2,650,000 1,574,000 1,249,000 1,256,000 1,251,000 813,000 733,000 768,000 689,000 572,000 546,000 537,000 492,000 620,000 658,000 675,000 739,000 738,000 1,096,000 1,173,000 1,225,000 1,236,000 1,283,000 1,383,000 1,845,000 1,748,000 1,749,000 1,898,000 1,953,000 1,805,000 1,794,000 1,735,000 1,801,000 1,501,000 1,521,000 1,468,000 1,264,000 1,076,000 441,000 
          change in fair value of warrant liability
        		 0 0 -2,012,000 -25,129,000 2,347,000 32,846,000                                 
          loss from equity method investment
        		599,000 707,000 323,000 389,000 539,000 2,174,000 682,000   1,404,000 865,000 1,284,000 1,731,000 4,638,000 2,730,000 1,596,000 1,041,000 2,559,000 1,709,000 463,000 100,000                   
          changes in operating assets and liabilities:
        		                                       
          accounts receivable - related party
        		-6,000 -5,000 54,000 -7,000 -4,000 -5,000 -35,000   -15,000 -11,000 429,000 159,000 -85,000 -130,000 0 134,000 -231,000                      
          prepaid and other current assets
        		-1,762,000 -204,000 64,000 -87,000 1,168,000 -1,168,000 -223,000 -280,000 84,000 134,000 -22,000 -238,000 118,000 379,000 637,000 -739,000 304,000 798,000 508,000 -1,820,000 237,000 71,000 155,000 -167,000 226,000 49,000 -106,000 -108,000 -205,000 895,000      63,000 429,000   
          operating lease right-of-use asset
        		88,000 88,000 85,000 83,000 82,000 -893,000 294,000 287,000 284,000 274,000 268,000 262,000 264,000 250,000 245,000 240,000 238,000 230,000 -2,156,000 191,000 193,000 177,000 171,000 167,000 164,000               
          other assets
        		-865,000 -3,000 -226,000 3,000 3,000 -380,000 -123,000   0    119,000    43,000 37,000 762,000 -664,000 66,000 21,000   0 0 1,000 -51,000 0 729,000         
          accounts payable
        		2,206,000 517,000 -1,163,000 1,829,000 -1,274,000 709,000 660,000 -396,000 84,000 121,000 -694,000 691,000 -569,000 -2,251,000 1,828,000 210,000 624,000 -769,000 -531,000 -2,045,000 1,443,000 896,000 -208,000 -577,000 908,000 538,000 -728,000 374,000 266,000 113,000 -370,000 -1,244,000 45,000 -610,000 1,763,000 559,000 1,002,000   
          accrued and other liabilities
        		499,000 765,000 708,000 1,142,000 146,000 -490,000 -89,000 233,000 101,000 -589,000 98,000 -1,159,000 -1,928,000 -1,022,000 2,199,000 385,000 -1,095,000 -875,000 -386,000 451,000 287,000 -800,000 606,000 369,000 530,000 299,000 -484,000 1,660,000 555,000 -813,000 -1,660,000 418,000 1,597,000 1,025,000 229,000 1,121,000 888,000 302,000 618,000 
          operating lease liability
        		-103,000 -74,000 -72,000 -70,000 31,000 768,000 -346,000 -340,000 -334,000 -316,000 -309,000 -304,000 -298,000 -269,000 -264,000 -259,000 -254,000 -238,000 2,101,000 -266,000 -260,000 -227,000 -223,000 -217,000 -211,000               
          net cash from operating activities
        		-10,374,000 -9,191,000 -9,566,000 -5,777,000 -8,263,000 -8,465,000 -6,321,000 -5,481,000 -5,157,000 -5,167,000 -5,434,000 -5,223,000 -8,111,000 -7,547,000 -6,929,000 -6,123,000 -6,424,000 -6,856,000 -8,425,000 -12,647,000 -8,787,000 -8,207,000 -7,732,000 -9,486,000 -9,353,000 -8,510,000 -10,607,000 -9,214,000 -8,990,000 -8,257,000 -10,797,000         
          capital expenditures
        		-91,000 -25,000 0 -113,000 -36,000 0 0 0  0 0 0 -34,000 0 -265,000 0  0 0 0 0 0 0 0  -5,000 -4,000 0 0 -57,000 -160,000         
          free cash flows
        		-10,465,000 -9,216,000 -9,566,000 -5,890,000 -8,299,000 -8,465,000 -6,321,000 -5,481,000  -5,167,000 -5,434,000 -5,223,000 -8,145,000 -7,547,000 -7,194,000 -6,123,000  -6,856,000 -8,425,000 -12,647,000 -8,787,000 -8,207,000 -7,732,000 -9,486,000  -8,515,000 -10,611,000 -9,214,000 -8,990,000 -8,314,000 -10,957,000         
          cash flows from investing activities
        		                                       
          purchases of marketable securities
        		-161,737,000 -13,418,000 -31,149,000 -39,475,000 -7,708,000 -20,361,000 -18,836,000 -26,294,000 -4,628,000 -11,425,000 -1,815,000 -20,719,000 -13,089,000 -19,301,000 -17,470,000 -3,036,000 -26,384,000 -4,494,000 -154,000 -1,388,000 -3,321,000 -7,076,000 -5,730,000 -18,323,000 -11,411,000 -23,713,000 -50,371,000 -34,599,000 -29,903,000 -32,056,000 -30,350,000         
          maturities of marketable securities
        		16,982,000 24,323,000 28,531,000 19,287,000 11,987,000 14,273,000 14,946,000 8,790,000 4,621,000 9,107,000 19,361,000 16,430,000 17,725,000 15,397,000 20,775,000 6,180,000 810,000 2,500,000 3,625,000 16,630,000 8,167,000 7,539,000 15,745,000 24,993,000 38,099,000 28,313,000 39,850,000 35,015,000 38,688,000 38,725,000 53,820,000 20,056,000 19,423,000 48,700,000 64,500,000 36,300,000 20,000,000 61,925,000 33,000,000 
          purchases of property and equipment
        		-91,000 -25,000 0 -113,000 -36,000     0 0 0 -34,000 0 -265,000       0    -5,000 -4,000             
          net cash from investing activities
        		-144,846,000 10,880,000 -2,618,000 -20,301,000 4,243,000 -6,083,000 -3,890,000 -17,504,000 -7,000 -2,318,000 17,546,000 -4,289,000 4,602,000 -3,882,000 3,040,000 3,140,000 -25,574,000 -1,999,000 3,471,000 15,242,000 4,846,000 463,000 9,939,000 6,670,000 27,697,000 4,595,000 -10,525,000 416,000 8,769,000    3,620,000 20,657,000 35,319,000 18,177,000    
          cash flows from financing activities
        		                                       
          proceeds from issuance of common stock in connection with follow-on public offering
        		189,407,000                                       
          proceeds from exercise of common stock options
        		1,339,000 20,000 360,000 25,000 279,000 18,000    0 8,000 0 4,000     18,000    1,000 64,000   2,000 16,000 5,000 1,000 172,000 166,000 48,000 7,000 126,000 0 8,000    
          net cash from financing activities
        		190,746,000 20,000 360,000 35,770,000 279,000 18,608,000 50,000   0 335,000 7,516,000 4,000     18,000 18,334,000 11,216,000 32,590,000 1,223,000 64,000   2,000 16,000 5,000 1,000 172,000 166,000 48,000 64,884,000 126,000 0 8,000 0   
          net increase in cash and cash equivalents
        		35,526,000         -7,485,000    -11,429,000 -3,889,000 -2,983,000 -31,998,000 -8,837,000 13,380,000 13,811,000 28,649,000 -6,521,000 2,271,000 -2,793,000 18,344,000    -220,000 -1,551,000 12,679,000 -74,497,000 57,459,000 10,009,000 23,608,000 5,437,000 1,233,000   
          cash and cash equivalents at beginning of the period
        		4,576,000 0 0 0 8,740,000 0 0 0 12,620,000 0 0 0 13,159,000 0 0 0 63,458,000 0 0 0 16,455,000 0 0 0 5,154,000 0 0 0 39,196,000 0 0 0 45,106,000 0 0 5,050,000 0 0 4,105,000 
          cash and cash equivalents at end of the period
        		40,102,000 1,709,000 -11,824,000 9,692,000 4,999,000 4,060,000 -10,161,000 7,385,000 7,456,000 -7,485,000 12,447,000 -1,996,000 9,654,000 -11,429,000 -3,889,000 -2,983,000 31,460,000 -8,837,000 13,380,000 13,811,000 45,104,000 -6,521,000 2,271,000 -2,793,000 23,498,000 -3,913,000 -21,116,000 -8,793,000 38,976,000 -1,551,000 12,679,000 -74,497,000 102,565,000 10,009,000 23,608,000 10,487,000 1,233,000 278,000 4,065,000 
          supplemental disclosures of cash flow information
        		                                       
          offering costs recorded to additional paid-in-capital but not paid
        		553,000                                       
          gain from sale of property and equipment
        		                                       
          proceeds from sale of property and equipment
        		                                       
          proceeds from issuance of common stock
        		     0 0           0 0 0 31,989,000         0 0 0 64,877,000       
          proceeds from issuance of pre-funded warrants
        		     0 0                                 
          proceeds from issuance of common warrants
        		     0 0                                 
          proceeds from the exercise of common stock warrants
        		 0 0                                     
          proceeds from issuance of common stock in connection with at-the-market offering
        		         0 327,000       0 17,137,000 11,216,000 601,000                   
          net decrease in cash and cash equivalents
        		 1,709,000   -3,741,000   7,385,000 -5,164,000   -1,996,000 -3,505,000             -3,913,000 -21,116,000             
          reclassification of common stock warrant liability into additional paid-in capital upon exercise of common stock warrants
        		                                       
          right-of-use asset obtained in exchange for operating lease liability
        		                                       
          net income
        		   -7,998,000 15,193,000                                   
          adjustments to reconcile net income to net cash from operating activities:
        		                                       
          income from equity method investment
        		        -236,000                               
          purchases of property and equipment incurred but not paid
        		                            16,000 78,000      46,000 111,000 -188,000 199,000 
          gain on deconsolidation of angel pharmaceuticals
        		                                       
          sales of marketable securities
        		                     0 0 0 1,009,000               
          other long-term liabilities
        		                             243,000 -116,000      -89,000 55,000 581,000 
          other
        		                          -39,000 -33,000 119,000           
          purchase of property and equipment
        		                            -16,000 -135,000 -160,000         
          net cash from (used) in investing activities
        		                             6,534,000 23,310,000         
          depreciation
        		                                 211,000 208,000 204,000 159,000 144,000 106,000 
          amortization related to marketable securities
        		                                       
          proceeds from issuance of common stock, net of issuance costs
        		                                       
          amortization/accretion related to marketable securities
        		                                    209,000 205,000 105,000 
          ipo costs incurred but not paid
        		                                      301,000 
          change in fair value of convertible preferred stock liability
        		                                       
          proceeds from issuance of common stock in ipo, net of issuance costs
        		                                    0 7,012,000 64,343,000 
          proceeds from issuance of convertible preferred stock, net of issuance costs
        		                                       
          convertible preferred stock issuance costs incurred but not paid
        		                                       
          net cash provided by financing activities
        		                                      64,343,000 
          net (decrease) increase in cash and cash equivalents
        		                                       
          convertible preferred stock liability